STOCK TITAN

SCYNEXIS (SCYX) DEF 14A Filings

SCYX NASDAQ

Here are the DEF 14A proxy statements from SCYNEXIS, Inc. (SCYX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow SCYX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCYX filings page.

Rhea-AI Summary

SCYNEXIS, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 25, 2026. Proposals include electing six directors, ratifying Deloitte & Touche LLP, an advisory say-on-pay vote and say-on-pay frequency, and governance items.

The company seeks approval to amend its 2024 Equity Incentive Plan to increase the share reserve by 9,600,000 shares and to amend its certificate of incorporation to raise authorized common stock to either 60,000,000 or 300,000,000 shares, depending on a separate reverse stock split outcome. SCYNEXIS had 79,442,633 shares of common stock outstanding and entitled to vote as of April 27, 2026.

Rhea-AI Summary

SCYNEXIS, Inc. is calling a virtual special stockholder meeting on May 19, 2026 to seek approval for a reverse stock split of its common stock at a ratio between 1‑for‑5 and 1‑for‑10, along with a proportional reduction in authorized shares. The board states this flexibility is intended to help the company regain compliance with The Nasdaq Capital Market’s minimum bid price requirement before June 15, 2026 and avoid potential delisting proceedings. As of April 20, 2026, the company had 79,442,633 common shares outstanding and 150,000,000 authorized, which would all be reduced proportionately if the split is implemented.